GlassScriptPhysician profile
Waqas A Ghumman
NPI 1619931516
$276,023.07
in general payments reported to CMS, 2019-2025
34 companies · $11K in 2025
The $11K reported for 2025 was more than what 78% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89K · 2020: $16K · 2021: $32K · 2022: $64K · 2023: $34K · 2024: $30K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $32K · Honoraria: $31K · Food and Beverage: $6,751 · Travel and Lodging: $5,597 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,530.00 |
| Honoraria | $30,600.00 |
| Food and Beverage | $6,750.60 |
| Travel and Lodging | $5,597.16 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $125,245.02 | 2019-2025 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54,231.00 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $48,915.51 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $19,638.92 | 2019-2025 | Farxiga, Wainua |
| Lilly USA, LLC | $15,937.61 | 2020-2025 | Jardiance |
| Abbott Laboratories | $6,225.30 | 2019-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Aveir, Cardiomems |
| Pfizer INC. | $925.88 | 2019-2024 | |
| Actelion Pharmaceuticals US, INC. | $914.60 | 2020-2025 | Uptravi, Opsumit, Opsynvi |
| United Therapeutics Corporation | $701.37 | 2021-2025 | Tyvaso, Tyvaso, Remodulin |
| Cvrx, INC. | $386.43 | 2019-2025 | Barostim Neo System |
| Impulse Dynamics (USA) INC. | $323.80 | 2021-2024 | Optimizer |
| Bayer Healthcare Pharmaceuticals INC. | $289.07 | 2020-2025 | |
| Kestra Medical Technology Services, INC. | $268.23 | 2024-2025 | Assure Wcd |
| Merck Sharp & Dohme LLC | $203.39 | 2023-2025 | Verquvo, Winrevair |
| Alnylam Pharmaceuticals INC. | $179.83 | 2020-2025 | Onpattro |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $175.52 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $167.30 | 2022-2025 | Camzyos |
| Edwards Lifesciences Corporation | $159.09 | 2019-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Medtronic Vascular, INC. | $156.25 | 2019-2020 | |
| Amgen INC. | $140.65 | 2023-2025 | Repatha, Repatha |
| Akcea Therapeutics, INC. | $117.68 | 2019-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $114.92 | 2019-2025 | Lifevest |
| Biotronik INC. | $101.41 | 2025 | Orsiro Mission |
| Novo Nordisk INC | $90.86 | 2024-2025 | Wegovy |
| Bridgebio Pharma, INC. | $90.59 | 2025 | Attruby |
| Medtronic, INC. | $85.57 | 2021-2024 | Mc3 Nautilus(Tm) Ecmo Oxygenator, Corevalve Evolut R |
| Scpharmaceuticals INC. | $44.20 | 2023-2024 | |
| Vifor Pharma, INC. | $42.31 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $41.03 | 2024 | |
| Biosense Webster, INC. | $28.64 | 2023 | Soundstar |
| Endotronix, INC. | $24.08 | 2025 | Cordella Pulomonary Artery Pressure Sensor |
| Heartflow, INC. | $19.74 | 2022 | |
| Janssen Pharmaceuticals, INC | $18.79 | 2023 | Xarelto |
| Sobi, INC | $18.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Waqas Ghumman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.